Navigation Links
US FDA licenses Sanofi Pasteur's new pediatric combination vaccine, pentacel
Date:6/23/2008

Swiftwater, PA - Lyon, France - June 23, 2008 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Pentacel®, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine. Pentacel® vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b (Hib). Pentacel® vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to fifth birthday).

Pentacel® vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.

Pentacel® vaccine is approved for administration as a four-dose series at 2, 4, 6 and 15-18 months of age. The first dose may be given as early as 6 weeks of age. According to the current Recommended Childhood Immunization Schedule of the U.S. Centers for Disease Control and Prevention (CDC), up to 23 injections are needed by the time a child reaches 18 months of age with single-entity vaccines. The use of Pentacel® vaccine could reduce that number of shots by seven.

"Pentacel® vaccine will help simplify the immunization schedule by reducing the number of injections infants and young children will receive in their first two years of life," said Wayne Pisano, President and Chief Executive Officer, sanofi pasteur. Pentacel® vaccine has been used in Canada for a decade and is licensed in seven other countries. "We are pleased that the U.S. FDA has now taken this important step, to make the convenience of Pentacel® vaccine available to health-care providers and parents in the U.S.," Pisano added.

"The FDA approval of Pentacel® vaccine is great new
'/>"/>

Contact: Len Lavenda
len.lavenda@sanofipasteur.com
570-839-4446
Publicis Consultants | PR
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
2. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
3. NuVasive Licenses Its Insert and Rotate Technology
4. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
5. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Cyberonics Licenses Obesity-Related Patents
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Chronic Fatigue Syndrome has been ... with unexplained fatigue lasting 6 months or longer. Symptoms ... and concentration impairment, muscle and joint pain without swelling ... sleep and malaise that lasts for more than 24 ... to be linked to insulin resistance. At a healthy ...
(Date:5/24/2013)... May 24, 2013 DiaperBuys.com is pleased ... Photo Contest. Lindsey Willis of Olathe, Kansas, won the ... from DiaperBuys. Second prize was a three-month supply of ... Las Vegas, Nev.; and third prize, a one-month supply, ... contest was run through the company’s Facebook page. Entrants ...
(Date:5/24/2013)... 2013 Scott Ryan Tischler of Tischler ... lose 200 lbs. of fat in just over a ... younger brother the importance of exercising. Scott also taught ... to these 7 rules of healthy eating and having ... be accomplished. , 1.    Find a distraction when a food ...
(Date:5/23/2013)... Over the past decade, the traditional ... has affected the Medical Group Practice Management industry ... hours, more young physicians are opting out of private ... says IBISWorld industry analyst Anna Son. In addition, “faced ... of older physicians are selling their practices and moving ...
(Date:5/23/2013)... Whether working in an urban setting or a ... an added layer of protection at night. The ... is an effective portable, rugged, rapidly deployable wireless infrared ... and perimeter security. , Today, ARA announces that government ... the past three years, with most systems deployed within ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:DiaperBuys.com Announces Photo Contest Winners 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3
... a prestigious international healthcare and wellness center, will implement the ... Cypress Communications®. , ... Atlanta, GA ... healthcare and wellness center, will implement the C4 IP™ ...
... resident M. Michael Wolfe, MD, chief of the Gastroenterology ... research professor of physiology and biophysics at Boston University ... Top Doctors by Castle Connolly Medical Ltd. , The ... medical care, is a trusted and authoritative resource for ...
... been diagnosed with panic attacks or panic disorder have ... suffering a heart attack than the normal population, with ... published in Europe,s leading cardiology journal, the European ... , The study found that people who were younger ...
... WASHINGTON -- The U.S. Environmental Protection Agency should examine ... cause adverse health effects in humans, says a new ... this analysis, called a cumulative risk assessment, should consider ... effects as phthalates, instead of focusing on chemicals that ...
... prescribed for men with chronic prostatitis, a painful disorder ... significantly reduce symptoms in recently diagnosed men who had ... a clinical trial sponsored by the National Institute of ... the National Institutes of Health (NIH). The study is ...
... people know that how we live our lives effects our ... a healthy lifestyle? Why do health professionals like doctors ... public policy, health services, schools and education, the workplace, the ... support healthier living? For instance, can exercise help with addiction? ...
Cached Medicine News:Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 3Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 4Health News:Boston University Medical Center gastroenterologist 2Health News:Panic attacks linked to higher risk of heart attacks and heart disease, especially in younger people 2Health News:Panic attacks linked to higher risk of heart attacks and heart disease, especially in younger people 3Health News:EPA should pursue cumulative risk assessment of phthalates and other chemicals 2Health News:EPA should pursue cumulative risk assessment of phthalates and other chemicals 3Health News:Common treatment for chronic prostatitis fails to reduce symptoms 2Health News:New Year starts with focus on healthy living 2Health News:New Year starts with focus on healthy living 3
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
(Date:5/23/2013)... ARBOR, Mich. , May 23, 2013  Every day, ... flow of air to his lungs. April and ... the dire predictions weren,t true. "Quite a few ... the hospital alive," says April Gionfriddo , ... were desperate. Anything that would work, we would take it ...
(Date:5/23/2013)... Mass. , May 23, 2013  Spring Bank ... the treatment of viral infections, today announced that it ... SB 9200, its investigational, once daily, oral therapy for ... in healthy, HCV-infected patients and is designed to assess ... SB 9200 is a first-in-class drug for the treatment ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... Sept. 26 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... trial of glufosfamide plus gemcitabine were presented at ... Spain. In the Phase 2 clinical trial ... of advanced pancreatic cancer, six-month and,one-year survival were ...
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... (Ibis), has been awarded a subcontract,of a National ... influenza,surveillance research through application of the Ibis T5000(TM) ... Ibis and the Lovelace,Respiratory Research Institute (LRRI) and ...
Cached Medicine Technology:Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 4Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 2Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 3Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 4Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 5
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
Sealing tape, slightly stiffer than Polyolefin tape....
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Medicine Products: